<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD with MathML3 v1.1 20151215//EN" "JATS-journalpublishing1-mathml3.dtd">
<article dtd-version="1.1"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:mml="http://www.w3.org/1998/Math/MathML">
    <front>
        <journal-meta>
            <journal-id></journal-id>
            <issn></issn>
        </journal-meta>
        <article-meta>
            <title-group>
                <article-title></article-title>
            </title-group>
            <pub-date>
                <year></year>
            </pub-date>
        </article-meta>
    </front>
    <back>
        <ref-list>
            <ref id="b1">
                <label>1. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Vallianou</surname>
                            <given-names>NG</given-names>
                        </name>, 
                        <name>
                            <surname>Geladari</surname>
                            <given-names>E</given-names>
                        </name>, 
                        <name>
                            <surname>Kazazis</surname>
                            <given-names>CE</given-names>
                        </name>
                    </person-group>. 
                    <article-title>SGLT-2 inhibitors: their pleiotropic properties</article-title>. 
                    <source>Diabetes Metab Syndr</source>. 
                    <year>2017</year>
                    <month>Oct - Dec</month>;
                    <volume>11</volume>(
                    <issue>4</issue>):
                    <fpage>311</fpage>–
                    <lpage>5</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.dsx.2016.12.003</pub-id>
                    <pub-id pub-id-type="pmid">28011230</pub-id>
                    <issn>1871-4021</issn>
                </mixed-citation>
            </ref>
            <ref id="b2">
                <label>2. </label>
                <mixed-citation publication-type="webpage">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Diabetes Atlas</surname>
                            <given-names>ID</given-names>
                        </name>
                    </person-group>.
                    <source>IDF Diabetes Atlas</source>. 
                    <edition>8th edition 2017</edition>.
                    [<date-in-citation content-type="access-date" iso-8601-date="2017-03-22">cited 2017 Mar 22</date-in-citation>]. 
                    <comment>Available from:<uri>http://www.diabetesatlas.org/#</uri></comment>.
                </mixed-citation>
            </ref>
            <ref id="b3">
                <label>3. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Storgaard</surname>
                            <given-names>H</given-names>
                        </name>, 
                        <name>
                            <surname>Gluud</surname>
                            <given-names>LL</given-names>
                        </name>, 
                        <name>
                            <surname>Bennett</surname>
                            <given-names>C</given-names>
                        </name>, 
                        <name>
                            <surname>Grøndahl</surname>
                            <given-names>MF</given-names>
                        </name>, 
                        <name>
                            <surname>Christensen</surname>
                            <given-names>MB</given-names>
                        </name>, 
                        <name>
                            <surname>Knop</surname>
                            <given-names>FK</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis</article-title>. 
                    <source>PLoS One</source>. 
                    <year>2016</year>
                    <month>Nov</month>;
                    <volume>11</volume>( 
                    <issue>11</issue>):
                    <fpage>e0166125</fpage>. 
                    <pub-id pub-id-type="doi">10.1371/journal.pone.0166125</pub-id>
                    <pub-id pub-id-type="pmid">27835680</pub-id>
                    <issn>1932-6203</issn>
                </mixed-citation>
            </ref>
            <ref id="b4">
                <label>4. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Ivo-Dos-Santos</surname>
                            <given-names>J</given-names>
                        </name>, 
                        <name>
                            <surname>Campos</surname>
                            <given-names>DL</given-names>
                        </name>, 
                        <name>
                            <surname>Galvão-Castro</surname>
                            <given-names>B</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Patterns of serologic response to human immunodeficiency virus type 1 (HIV-1) in Brazilians with different clinical forms of HIV infection</article-title>. 
                    <source>Mem Inst Oswaldo Cruz</source>. 
                    <year>1989</year>
                    <month>Jan-Mar</month>;
                    <volume>84</volume>(
                    <issue>1</issue>):
                    <fpage>9</fpage>–
                    <lpage>11</lpage>. 
                    <pub-id pub-id-type="doi">10.1590/S0074-02761989000100003</pub-id>
                    <pub-id pub-id-type="pmid">2319954</pub-id>
                    <issn>0074-0276</issn>
                </mixed-citation>
            </ref>
            <ref id="b5">
                <label>5. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Kalra</surname>
                            <given-names>S</given-names>
                        </name>, 
                        <name>
                            <surname>Singh</surname>
                            <given-names>V</given-names>
                        </name>, 
                        <name>
                            <surname>Nagrale</surname>
                            <given-names>D</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review</article-title>. 
                    <source>Adv Ther</source>. 
                    <year>2016</year>
                    <month>Sep</month>;
                    <volume>33</volume>(
                    <issue>9</issue>):
                    <fpage>1502</fpage>–
                    <lpage>18</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s12325-016-0379-5</pub-id>
                    <pub-id pub-id-type="pmid">27423646</pub-id>
                    <issn>0741-238X</issn>
                </mixed-citation>
            </ref>
            <ref id="b6">
                <label>6. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Kalra</surname>
                            <given-names>S</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology</article-title>. 
                    <source>Diabetes Ther</source>. 
                    <year>2014</year>
                    <month>Dec</month>;
                    <volume>5</volume>(
                    <issue>2</issue>):
                    <fpage>355</fpage>–
                    <lpage>66</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s13300-014-0089-4</pub-id>
                    <pub-id pub-id-type="pmid">25424969</pub-id>
                    <issn>1869-6953</issn>
                </mixed-citation>
            </ref>
            <ref id="b7">
                <label>7. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Lioudaki</surname>
                            <given-names>E</given-names>
                        </name>, 
                        <name>
                            <surname>Androulakis</surname>
                            <given-names>ES</given-names>
                        </name>, 
                        <name>
                            <surname>Whyte</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Stylianou</surname>
                            <given-names>KG</given-names>
                        </name>, 
                        <name>
                            <surname>Daphnis</surname>
                            <given-names>EK</given-names>
                        </name>, 
                        <name>
                            <surname>Ganotakis</surname>
                            <given-names>ES</given-names>
                        </name>
                    </person-group>. 
                    <article-title>The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action</article-title>. 
                    <source>Cardiovasc Drugs Ther</source>. 
                    <year>2017</year>
                    <month>Apr</month>;
                    <volume>31</volume>(
                    <issue>2</issue>):
                    <fpage>215</fpage>–
                    <lpage>25</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s10557-017-6724-3</pub-id>
                    <pub-id pub-id-type="pmid">28444472</pub-id>
                    <issn>0920-3206</issn>
                </mixed-citation>
            </ref>
            <ref id="b8">
                <label>8. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Martens</surname>
                            <given-names>P</given-names>
                        </name>, 
                        <name>
                            <surname>Mathieu</surname>
                            <given-names>C</given-names>
                        </name>, 
                        <name>
                            <surname>Verbrugge</surname>
                            <given-names>FH</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Promise of SGLT2 Inhibitors in Heart Failure: diabetes and Beyond</article-title>. 
                    <source>Curr Treat Options Cardiovasc Med</source>. 
                    <year>2017</year>
                    <month>Mar</month>;
                    <volume>19</volume>(
                    <issue>3</issue>):
                    <fpage>23</fpage>. 
                    <pub-id pub-id-type="doi">10.1007/s11936-017-0522-x</pub-id>
                    <pub-id pub-id-type="pmid">28299616</pub-id>
                    <issn>1092-8464</issn>
                </mixed-citation>
            </ref>
            <ref id="b9">
                <label>9. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Zinman</surname>
                            <given-names>B</given-names>
                        </name>, 
                        <name>
                            <surname>Lachin</surname>
                            <given-names>JM</given-names>
                        </name>, 
                        <name>
                            <surname>Inzucchi</surname>
                            <given-names>SE</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes</article-title>. 
                    <source>N Engl J Med</source>. 
                    <year>2016</year>
                    <month>Mar</month>;
                    <volume>374</volume>(
                    <issue>11</issue>):
                    <fpage>1094</fpage>.
                    <pub-id pub-id-type="pmid">26981940</pub-id>
                    <issn>1533-4406</issn>
                </mixed-citation>
            </ref>
            <ref id="b10">
                <label>10. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Farahani</surname>
                            <given-names>P</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Non-severe Hypoglycemia Risk Difference between Sulfonylurea and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2-I) as an Add-On to Metformin in Randomized Controlled Trials</article-title>. 
                    <source>J Popul Ther Clin Pharmacol</source>. 
                    <year>2017</year>
                    <month>May</month>;
                    <volume>24</volume>(
                    <issue>2</issue>):
                    <fpage>e32</fpage>–
                    <lpage>40</lpage>. 
                    <pub-id pub-id-type="doi">10.22374/1710-6222.24.2.6</pub-id>
                    <pub-id pub-id-type="pmid">28594482</pub-id>
                    <issn>1710-6222</issn>
                </mixed-citation>
            </ref>
            <ref id="b11">
                <label>11. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Cai</surname>
                            <given-names>X</given-names>
                        </name>, 
                        <name>
                            <surname>Yang</surname>
                            <given-names>W</given-names>
                        </name>, 
                        <name>
                            <surname>Gao</surname>
                            <given-names>X</given-names>
                        </name>, 
                        <name>
                            <surname>Chen</surname>
                            <given-names>Y</given-names>
                        </name>, 
                        <name>
                            <surname>Zhou</surname>
                            <given-names>L</given-names>
                        </name>, 
                        <name>
                            <surname>Zhang</surname>
                            <given-names>S</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis</article-title>. 
                    <source>Obesity (Silver Spring)</source>. 
                    <year>2018</year>
                    <month>Jan</month>;
                    <volume>26</volume>(
                    <issue>1</issue>):
                    <fpage>70</fpage>–
                    <lpage>80</lpage>. 
                    <pub-id pub-id-type="doi">10.1002/oby.22066</pub-id>
                    <pub-id pub-id-type="pmid">29165885</pub-id>
                    <issn>1930-7381</issn>
                </mixed-citation>
            </ref>
            <ref id="b12">
                <label>12. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Ahmadieh</surname>
                            <given-names>H</given-names>
                        </name>, 
                        <name>
                            <surname>Azar</surname>
                            <given-names>S</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Effects of Sodium Glucose Cotransporter-2 Inhibitors on Serum Uric Acid in Type 2 Diabetes Mellitus</article-title>. 
                    <source>Diabetes Technol Ther</source>. 
                    <year>2017</year>
                    <month>Sep</month>;
                    <volume>19</volume>(
                    <issue>9</issue>):
                    <fpage>507</fpage>–
                    <lpage>12</lpage>. 
                    <pub-id pub-id-type="doi">10.1089/dia.2017.0070</pub-id>
                    <pub-id pub-id-type="pmid">28749169</pub-id>
                    <issn>1520-9156</issn>
                </mixed-citation>
            </ref>
            <ref id="b13">
                <label>13. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Shyangdan</surname>
                            <given-names>DS</given-names>
                        </name>, 
                        <name>
                            <surname>Uthman</surname>
                            <given-names>OA</given-names>
                        </name>, 
                        <name>
                            <surname>Waugh</surname>
                            <given-names>N</given-names>
                        </name>
                    </person-group>. 
                    <article-title>SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis</article-title>. 
                    <source>BMJ Open</source>. 
                    <year>2016</year>
                    <month>Feb</month>;
                    <volume>6</volume>(
                    <issue>2</issue>):
                    <fpage>e009417</fpage>. 
                    <pub-id pub-id-type="doi">10.1136/bmjopen-2015-009417</pub-id>
                    <pub-id pub-id-type="pmid">26911584</pub-id>
                    <issn>2044-6055</issn>
                </mixed-citation>
            </ref>
            <ref id="b14">
                <label>14. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Cherney</surname>
                            <given-names>DZ</given-names>
                        </name>, 
                        <name>
                            <surname>Perkins</surname>
                            <given-names>BA</given-names>
                        </name>, 
                        <name>
                            <surname>Soleymanlou</surname>
                            <given-names>N</given-names>
                        </name>, 
                        <name>
                            <surname>Har</surname>
                            <given-names>R</given-names>
                        </name>, 
                        <name>
                            <surname>Fagan</surname>
                            <given-names>N</given-names>
                        </name>, 
                        <name>
                            <surname>Johansen</surname>
                            <given-names>OE</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus</article-title>. 
                    <source>Cardiovasc Diabetol</source>. 
                    <year>2014</year>
                    <month>Jan</month>;
                    <volume>13</volume>(
                    <issue>1</issue>):
                    <fpage>28</fpage>. 
                    <pub-id pub-id-type="doi">10.1186/1475-2840-13-28</pub-id>
                    <pub-id pub-id-type="pmid">24475922</pub-id>
                    <issn>1475-2840</issn>
                </mixed-citation>
            </ref>
            <ref id="b15">
                <label>15. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Fioretto</surname>
                            <given-names>P</given-names>
                        </name>, 
                        <name>
                            <surname>Zambon</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Rossato</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Busetto</surname>
                            <given-names>L</given-names>
                        </name>, 
                        <name>
                            <surname>Vettor</surname>
                            <given-names>R</given-names>
                        </name>
                    </person-group>. 
                    <article-title>SGLT2 Inhibitors and the Diabetic Kidney</article-title>. 
                    <source>Diabetes Care</source>. 
                    <year>2016</year>
                    <month>Aug</month>;
                    <volume>39</volume>
                    <supplement>Suppl 2</supplement>:
                    <fpage>S165</fpage>–
                    <lpage>71</lpage>. 
                    <pub-id pub-id-type="doi">10.2337/dcS15-3006</pub-id>
                    <pub-id pub-id-type="pmid">27440829</pub-id>
                    <issn>0149-5992</issn>
                </mixed-citation>
            </ref>
            <ref id="b16">
                <label>16. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Perrone-Filardi</surname>
                            <given-names>P</given-names>
                        </name>, 
                        <name>
                            <surname>Avogaro</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Bonora</surname>
                            <given-names>E</given-names>
                        </name>, 
                        <name>
                            <surname>Colivicchi</surname>
                            <given-names>F</given-names>
                        </name>, 
                        <name>
                            <surname>Fioretto</surname>
                            <given-names>P</given-names>
                        </name>, 
                        <name>
                            <surname>Maggioni</surname>
                            <given-names>AP</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Mechanisms linking empagliflozin to cardiovascular and renal protection</article-title>. 
                    <source>Int J Cardiol</source>. 
                    <year>2017</year>
                    <month>Aug</month>;
                    <volume>241</volume>:
                    <fpage>450</fpage>–
                    <lpage>6</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.ijcard.2017.03.089</pub-id>
                    <pub-id pub-id-type="pmid">28395981</pub-id>
                    <issn>0167-5273</issn>
                </mixed-citation>
            </ref>
            <ref id="b17">
                <label>17. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Rastogi</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Bhansali</surname>
                            <given-names>A</given-names>
                        </name>
                    </person-group>. 
                    <article-title>SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review</article-title>. 
                    <source>Diabetes Ther</source>. 
                    <year>2017</year>
                    <month>Dec</month>;
                    <volume>8</volume>(
                    <issue>6</issue>):
                    <fpage>1245</fpage>–
                    <lpage>51</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s13300-017-0320-1</pub-id>
                    <pub-id pub-id-type="pmid">29076040</pub-id>
                    <issn>1869-6953</issn>
                </mixed-citation>
            </ref>
            <ref id="b18">
                <label>18. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Zinman</surname>
                            <given-names>B</given-names>
                        </name>, 
                        <name>
                            <surname>Wanner</surname>
                            <given-names>C</given-names>
                        </name>, 
                        <name>
                            <surname>Lachin</surname>
                            <given-names>JM</given-names>
                        </name>, 
                        <name>
                            <surname>Fitchett</surname>
                            <given-names>D</given-names>
                        </name>, 
                        <name>
                            <surname>Bluhmki</surname>
                            <given-names>E</given-names>
                        </name>, 
                        <name>
                            <surname>Hantel</surname>
                            <given-names>S</given-names>
                        </name>, 
                        <etal>et al</etal>; 
                        <collab>EMPA-REG OUTCOME Investigators</collab>
                    </person-group>. 
                    <article-title>Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes</article-title>. 
                    <source>N Engl J Med</source>. 
                    <year>2015</year>
                    <month>Nov</month>;
                    <volume>373</volume>(
                    <issue>22</issue>):
                    <fpage>2117</fpage>–
                    <lpage>28</lpage>. 
                    <pub-id pub-id-type="doi">10.1056/NEJMoa1504720</pub-id>
                    <pub-id pub-id-type="pmid">26378978</pub-id>
                    <issn>0028-4793</issn>
                </mixed-citation>
            </ref>
            <ref id="b19">
                <label>19. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Neal</surname>
                            <given-names>B</given-names>
                        </name>, 
                        <name>
                            <surname>Perkovic</surname>
                            <given-names>V</given-names>
                        </name>, 
                        <name>
                            <surname>Mahaffey</surname>
                            <given-names>KW</given-names>
                        </name>, 
                        <name>
                            <surname>de Zeeuw</surname>
                            <given-names>D</given-names>
                        </name>, 
                        <name>
                            <surname>Fulcher</surname>
                            <given-names>G</given-names>
                        </name>, 
                        <name>
                            <surname>Erondu</surname>
                            <given-names>N</given-names>
                        </name>, 
                        <etal>et al</etal>; 
                        <collab>CANVAS Program Collaborative Group</collab>
                    </person-group>. 
                    <article-title>Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes</article-title>. 
                    <source>N Engl J Med</source>. 
                    <year>2017</year>
                    <month>Aug</month>;
                    <volume>377</volume>(
                    <issue>7</issue>):
                    <fpage>644</fpage>–
                    <lpage>57</lpage>. 
                    <pub-id pub-id-type="doi">10.1056/NEJMoa1611925</pub-id>
                    <pub-id pub-id-type="pmid">28605608</pub-id>
                    <issn>0028-4793</issn>
                </mixed-citation>
            </ref>
            <ref id="b20">
                <label>20. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Filippatos</surname>
                            <given-names>TD</given-names>
                        </name>, 
                        <name>
                            <surname>Tsimihodimos</surname>
                            <given-names>V</given-names>
                        </name>, 
                        <name>
                            <surname>Liamis</surname>
                            <given-names>G</given-names>
                        </name>, 
                        <name>
                            <surname>Elisaf</surname>
                            <given-names>MS</given-names>
                        </name>
                    </person-group>. 
                    <article-title>SGLT2 inhibitors-induced electrolyte abnormalities: an analysis of the associated mechanisms</article-title>. 
                    <source>Diabetes Metab Syndr</source>. 
                    <year>2018</year>
                    <month>Jan - Mar</month>;
                    <volume>12</volume>(
                    <issue>1</issue>):
                    <fpage>59</fpage>–
                    <lpage>63</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.dsx.2017.08.003</pub-id>
                    <pub-id pub-id-type="pmid">28826578</pub-id>
                    <issn>1871-4021</issn>
                </mixed-citation>
            </ref>
            <ref id="b21">
                <label>21. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Lytvyn</surname>
                            <given-names>Y</given-names>
                        </name>, 
                        <name>
                            <surname>Bjornstad</surname>
                            <given-names>P</given-names>
                        </name>, 
                        <name>
                            <surname>Udell</surname>
                            <given-names>JA</given-names>
                        </name>, 
                        <name>
                            <surname>Lovshin</surname>
                            <given-names>JA</given-names>
                        </name>, 
                        <name>
                            <surname>Cherney</surname>
                            <given-names>DZ</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials</article-title>. 
                    <source>Circulation</source>. 
                    <year>2017</year>
                    <month>Oct</month>;
                    <volume>136</volume>(
                    <issue>17</issue>):
                    <fpage>1643</fpage>–
                    <lpage>58</lpage>. 
                    <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.117.030012</pub-id>
                    <pub-id pub-id-type="pmid">29061576</pub-id>
                    <issn>0009-7322</issn>
                </mixed-citation>
            </ref>
            <ref id="b22">
                <label>22. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Rosenstock</surname>
                            <given-names>J</given-names>
                        </name>, 
                        <name>
                            <surname>Ferrannini</surname>
                            <given-names>E</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors</article-title>. 
                    <source>Diabetes Care</source>. 
                    <year>2015</year>
                    <month>Sep</month>;
                    <volume>38</volume>(
                    <issue>9</issue>):
                    <fpage>1638</fpage>–
                    <lpage>42</lpage>. 
                    <pub-id pub-id-type="doi">10.2337/dc15-1380</pub-id>
                    <pub-id pub-id-type="pmid">26294774</pub-id>
                    <issn>0149-5992</issn>
                </mixed-citation>
            </ref>
            <ref id="b23">
                <label>23. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Goldenberg</surname>
                            <given-names>RM</given-names>
                        </name>, 
                        <name>
                            <surname>Berard</surname>
                            <given-names>LD</given-names>
                        </name>, 
                        <name>
                            <surname>Cheng</surname>
                            <given-names>AY</given-names>
                        </name>, 
                        <name>
                            <surname>Gilbert</surname>
                            <given-names>JD</given-names>
                        </name>, 
                        <name>
                            <surname>Verma</surname>
                            <given-names>S</given-names>
                        </name>, 
                        <name>
                            <surname>Woo</surname>
                            <given-names>VC</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis</article-title>. 
                    <source>Clin Ther</source>. 
                    <year>2016</year>;
                    <month>Dec</month>;
                    <volume>38</volume>(
                    <issue>12</issue>):
                    <fpage>2654</fpage>–
                    <lpage>64</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.clinthera.2016.11.002</pub-id>
                    <pub-id pub-id-type="pmid">28003053</pub-id>
                    <issn>0149-2918</issn>
                </mixed-citation>
            </ref>
            <ref id="b24">
                <label>24. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Handelsman</surname>
                            <given-names>Y</given-names>
                        </name>, 
                        <name>
                            <surname>Henry</surname>
                            <given-names>RR</given-names>
                        </name>, 
                        <name>
                            <surname>Bloomgarden</surname>
                            <given-names>ZT</given-names>
                        </name>, 
                        <name>
                            <surname>Dagogo-Jack</surname>
                            <given-names>S</given-names>
                        </name>, 
                        <name>
                            <surname>DeFronzo</surname>
                            <given-names>RA</given-names>
                        </name>, 
                        <name>
                            <surname>Einhorn</surname>
                            <given-names>D</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of Sglt-2 Inhibitors and Diabetic Ketoacidosis</article-title>. 
                    <source>Endocr Pract</source>. 
                    <year>2016</year>
                    <month>Jun</month>;
                    <volume>22</volume>(
                    <issue>6</issue>):
                    <fpage>753</fpage>–
                    <lpage>62</lpage>. 
                    <pub-id pub-id-type="doi">10.4158/EP161292.PS</pub-id>
                    <pub-id pub-id-type="pmid">27082665</pub-id>
                    <issn>1530-891X</issn>
                </mixed-citation>
            </ref>
            <ref id="b25">
                <label>25. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Scheen</surname>
                            <given-names>AJ</given-names> 
                        </name>
                    </person-group>. 
                    <article-title>Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus</article-title>. 
                    <source>Drugs</source>. 
                    <year>2015</year>
                    <month>Jan</month>;
                    <volume>75</volume>(
                    <issue>1</issue>):
                    <fpage>33</fpage>–
                    <lpage>59</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s40265-014-0337-y</pub-id>
                    <pub-id pub-id-type="pmid">25488697</pub-id>
                    <issn>0012-6667</issn>
                </mixed-citation>
            </ref>
            <ref id="b26">
                <label>26. </label>
                <mixed-citation publication-type="book">
                    <person-group person-group-type="editor">
                        <name>
                            <surname>Zaletel</surname>
                            <given-names>J</given-names>
                        </name>, 
                        <name>
                            <surname>Ravnik Oblak</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <role>eds</role>
                    </person-group>. 
                    <source>Slovenske smernice za klinično obravnavo sladkorne bolezni tipa 2</source>. 
                    <edition>3th ed</edition>. 
                    <publisher-loc>Ljubljana</publisher-loc>:
                    <publisher-name>Klinični oddelek za endokrinologijo, diabetes in presnovne bolezni; Interna klinika UKC Ljubljana in Klinični oddelek za endokrinologijo, diabetes in bolezni presnove; Pediatrična klinika Ljubljana</publisher-name>;
                    <year>2016</year>.
                </mixed-citation>
            </ref>
        </ref-list>
    </back>
</article>
